AVEO PHARMACEUTICALS INC's ticker is AVEO and the CUSIP is 053588109. A total of 51 filers reported holding AVEO PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 0.06 and the average weighting 2.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $598,000 | -34.8% | 1,013,616 | -40.4% | 0.24% | -6.7% |
| Q4 2016 | $917,000 | -48.5% | 1,700,000 | -15.0% | 0.25% | -38.3% |
| Q3 2016 | $1,780,000 | -7.4% | 2,000,000 | 0.0% | 0.41% | -24.9% |
| Q2 2016 | $1,922,000 | -9.7% | 2,000,000 | -13.6% | 0.55% | +16.4% |
| Q1 2016 | $2,128,000 | -27.0% | 2,313,759 | 0.0% | 0.47% | -17.3% |
| Q4 2015 | $2,915,000 | +4.1% | 2,313,759 | 0.0% | 0.57% | -18.1% |
| Q3 2015 | $2,800,000 | -30.5% | 2,313,759 | 0.0% | 0.69% | -25.3% |
| Q2 2015 | $4,026,000 | +8.0% | 2,313,759 | -10.0% | 0.93% | +17.8% |
| Q1 2015 | $3,728,000 | +72.6% | 2,570,759 | 0.0% | 0.79% | +2.7% |
| Q4 2014 | $2,160,000 | -24.3% | 2,570,759 | 0.0% | 0.76% | -30.6% |
| Q3 2014 | $2,854,000 | -39.3% | 2,570,759 | 0.0% | 1.10% | -31.1% |
| Q2 2014 | $4,704,000 | +22.4% | 2,570,759 | 0.0% | 1.60% | +20.9% |
| Q1 2014 | $3,843,000 | -18.8% | 2,570,759 | 0.0% | 1.32% | -25.3% |
| Q4 2013 | $4,730,000 | – | 2,570,759 | – | 1.77% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greylock XI GP Limited Partnership | 584,004 | $1,068,000 | 100.00% |
| GREAT POINT PARTNERS LLC | 2,325,000 | $4,255,000 | 1.89% |
| Sarissa Capital Management LP | 2,570,759 | $4,704,000 | 1.60% |
| Deer VI & Co. LLC | 675,242 | $1,236,000 | 0.68% |
| Palo Alto Investors LP | 1,200,800 | $2,197,000 | 0.16% |
| Baupost Group | 3,829,350 | $7,008,000 | 0.11% |
| Gruss Capital Management LP | 533,253 | $976,000 | 0.05% |
| Granahan Investment Management | 676,451 | $1,238,000 | 0.04% |
| Fore Research & Management, LP | 674,200 | $1,233,000 | 0.04% |
| TFS CAPITAL LLC | 210,369 | $385,000 | 0.03% |